A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers by Golor, Georg et al.
© 2012 Golor et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Drug Design, Development and Therapy 2012:6 71–79
Drug Design, Development and Therapy
A first-in-man study to evaluate the safety, 
tolerability, and pharmacokinetics of pasireotide 
(SOM230), a multireceptor-targeted somatostatin 
analog, in healthy volunteers
Georg Golor1
Ke Hu2
Matthieu Ruffin3
Alexandra Buchelt3
Emmanuel Bouillaud3
Yanfeng Wang2
Mario Maldonado3
1PArExEL International GmbH, Berlin, 
Germany; 2Novartis Pharmaceuticals, 
East Hanover, NJ, USA; 3Novartis 
Pharma AG, Basel, Switzerland
Correspondence: Georg Golor 
Early Phase Clinical Unit – Berlin, 
PArExEL International GmbH,  
Klinikum Westend – Haus 18 
Spandauer Damm 130, 14050 Berlin, 
Germany 
Tel +49 030 30 685 158 
Fax +49 030 30 685 7017 
Email georg.golor@parexel.com
Abstract: Pasireotide (SOM230) is a multireceptor-targeted somatostatin analog with high 
binding affinity for four of the five somatostatin receptor subtypes (sst1,2,3 and sst5), and poten-
tial clinical activity in several neuroendocrine and oncologic conditions, including acromegaly, 
Cushing’s disease, and neuroendocrine tumors (NET). This manuscript reports the first-in-man 
dose-escalation study of pasireotide, evaluating its safety, tolerability, and pharmacokinetics (PK) 
in healthy male volunteers. A single dose of pasireotide 1–1200 µg was administered subcutane-
ously in four to eight subjects per dose level, with two additional subjects per cohort administered 
placebo. PK and safety evaluations were carried out over 7 days post-dose. Growth hormone 
(GH) suppression was evaluated using a GH-releasing hormone stimulation test on Day –1 and 
Day 1 at 3–5 hours post-injection. Seventy-two subjects completed the study. Pasireotide was 
well tolerated with no serious adverse events observed at any dose. Transient elevations in blood 
glucose levels were observed 2–6 hours after administration of pasireotide at doses between 200 
µg and 1200 µg, but this resolved without intervention by 23 hours post-dosing. The maximum 
tolerable dose was not established within the tested range. Pasireotide demonstrated a favor-
able PK profile with fast absorption (tmax: 0.25–0.5 hours), low clearance (CL/F: 8–13 L/hour), 
long effective elimination half-life (mean t½,β: 7–11 hours), and a proportional dose-exposure 
relationship. GH suppression of 79%–96% was observed at single pasireotide doses between 
200 µg and 1200 µg. In conclusion, pasireotide demonstrated favorable safety, tolerability, and 
PK profiles, as well as promising activity in suppressing the release of GH. The efficacy and 
safety of pasireotide is currently being evaluated in patients with acromegaly, Cushing’s disease, 
NET, and various non-neuroendocrine disorders.
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Introduction
Pasireotide is a multireceptor-targeted somatostatin analog that exerts its pharma  cologic 
activity through binding to somatostatin receptor subtypes (sst). The rationally designed 
cyclohexapeptide structure of pasireotide incorporates synthetic amino acids to achieve 
an enhanced sst binding profile compared with currently available somatostatin analogs 
octreotide and lanreotide (Table 1, Figure 1). Whereas octreotide and lanreotide bind 
with greatest affinity to sst2, pasireotide has high binding affinity for four of the five 
sst.1 Pasireotide has a 39-, 30- and 5-fold higher binding affinity for sst5, sst1, and sst3, 
respectively, and 2.6 times lower affinity for sst2 compared with octreotide.1 Pasireotide 
also has a 2-fold higher binding affinity for sst5 than endogenous somatostatin.2,3 More-
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Figure 1 Chemical structures of pasireotide, somatostatin (SRIF-14) and other somatostatin analogs. 
Notes: The molecular weights of pasireotide free base, somatostatin, octreotide and lanreotide are 1047 kDa, 1638 kDa, 1019 kDa, and 1096 kDa, respectively. The 
molecular weight of the pasireotide diaspartate salt form is 1313 kDa.
Table 1 Binding affinities of somatostatin (SRIF-14), pasireotide, octreotide, and lanreotide to the five human sst1
Compound sst1 sst2 sst3 sst4 sst5
Somatostatin (SRIF-14) 0.93 ± 0.12 0.15 ± 0.2 0.56 ± 0.17 1.50 ± 0.4 0.29 ± 0.04
Pasireotide 9.3 ± 0.1 1.0 ± 0.1 1.5 ± 0.3 .1000 0.16 ± 0.01
Octreotide 280 ± 80 0.38 ± 0.08 7.1 ± 1.4 .1000 6.3 ± 1.0
Lanreotide 180 ± 20 0.54 ± 0.08 14 ± 9 230 ± 40 17 ± 5
Notes: results are the mean ± SEM of IC50 values expressed as nmol/L. © European Society of Endocrinology 2002, reproduced with permission.1
over, pasireotide exhibits greater metabolic stability than 
octreotide because of the presence of a Cys–Cys bridge that 
protects the stability of the amide bond in the cyclic ring,1,4 
which may translate into a prolonged pharmacologic effect 
compared with octreotide.
Because of this unique binding profile and a more meta-
bolically stable chemical structure than octreotide, pasireotide 
may offer new opportunities for therapeutic application.1,5 
  Pasireotide is being evaluated in patients with acromegaly6–9 
and neuroendocrine tumors (NET),10,11 including patients 
who are resistant or refractory to octreotide LAR, as well 
as in medically naïve and/or de novo patients. Pasireotide 
also has potential to be a tumor-targeted management option 
for patients with Cushing’s disease, a patient population in 
whom currently available somatostatin analogs are ineffec-
tive. Pasireotide has demonstrated efficacy in patients with 
Cushing’s disease in a large, randomized, Phase III trial.12
This manuscript reports the results of the first-in-man 
study investigating the safety, tolerability, pharmacokinetics 
(PK), and pharmacodynamics (PD) of a single subcutaneous 
injection of pasireotide administered to healthy volunteers.
Methods
Subjects
Study subjects were male volunteers aged 18–40 years, in 
good health as determined by a suitable medical history and 
normal findings from evaluations performed at screening 
(eg, physical examination, vital signs, electrocardiograph, 
and laboratory tests). Subjects were enrolled only if their 
liver function tests, including serum glutamic oxaloacetic 
transaminase (SGOT, ie, aspartate transaminase) and serum 
glutamic pyruvic transaminase (SGPT, ie, alanine transami-
nase), were within the normal range; gamma-glutamyl 
transpeptidase (GGT) and alkaline phosphatase (ALP) did 
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not exceed twice the upper limit of the normal (ULN) range 
and serum bilirubin did not exceed 27 µmol/L (1.6 mg/dL). 
Subjects underwent a right-upper-quadrant abdominal 
ultrasound to rule out any cholelithiasis (symptomatic or 
asymptomatic gallstone disease).
Subjects were excluded from the trial if they had previous/
current gall bladder disease, pancreatic injury/pancreatitis, 
liver disease/injury, impaired renal function, autonomic 
dysfunction, acute or chronic bronchospastic disease, a clini-
cally significant drug/atopic allergy or had undergone major 
gastrointestinal tract surgery. Subjects were also excluded 
if they had taken any prescription or over-the-counter drugs 
(excluding paracetamol) within 2 weeks prior to dosing or 
donated $400 mL of blood within 8 weeks prior to pasire-
otide administration. Before enrolment into the trial, subjects 
were to abstain from strenuous physical exercise, alcohol, 
and caffeine starting 7 days, 72 hours, and 48 hours before 
pasireotide administration, respectively.
Study design
This was a single-center, randomized, double-blind, placebo-
controlled, time-lagged, parallel-group, ascending, single-
dose study of pasireotide subcutaneously administered to 
healthy volunteers. Pasireotide was administered between 
8 am and 9 am, approximately 1 hour after eating a light 
standardized meal. As such, the effect of pasireotide on blood 
glucose was investigated in a post-prandial state.
The study design called for eight subjects each to be 
randomized into seven cohorts of pasireotide 1, 2.5, 10, 30, 
100, 300 or 600 µg administered subcutaneously. Of these 
eight subjects, six in each cohort were to receive pasireotide 
and two were to receive placebo. A dispensing error resulted 
in four subjects being administered 200 µg pasireotide 
instead of 100 µg pasireotide. A protocol amendment allowed 
administration of 100 µg pasireotide to be restudied in new 
subjects, and an additional cohort administered 1200 µg 
pasireotide was included.
Pasireotide doses were administered to cohorts in ascend-
ing order. Before escalation to the next cohort, at least six sub-
jects from the previous cohort had to demonstrate adequate 
safety/tolerability for up to 48 hours post-dose. Subjects were 
confined to the study center from   approximately 36 hours 
before administration until the availability of 48-hour post-
dose safety results.
The study was randomized by a validated system. All 
subjects provided informed consent, and the study was con-
ducted in accordance with the Declaration of Helsinki (World 
Medical Association Inc, Ferney-Voltaire, France).
Study medication
Doses of 1, 2.5, 10, 30, 100, 300, 600, and 1200 µg of pasi-
reotide were administered subcutaneously. Pasireotide was 
provided as either 0.15 mg or 3 mg per 3 mL vials. For the 
1 µg and 2.5 µg doses, pasireotide solutions were prepared 
by diluting a 0.15 mg per 3 mL solution 5-fold in the match-
ing placebo solution to a final concentration of 0.03 mg per 
3 mL; doses of 1 µg and 2.5 µg were then administered as 
0.1 mL and 0.25 mL of the 5-fold diluted solution. Doses of 
10 µg and 30 µg were administered as 0.2 mL and 0.6 mL of 
the 0.15 mg per 3 mL solution, respectively, while doses of 
100, 200, 300, 600, and 1200 µg were administered as 0.1, 
0.2, 0.3, 0.6, and 1.2 mL of the 3 mg per 3 mL solution, 
respectively.
Safety, PK, and PD assessments
The primary objective of the study was to evaluate the safety 
and tolerability of a single subcutaneous dose of pasireotide 
in healthy subjects. Safety was assessed continuously 
throughout the study by physical examination, vital signs, 
blood pressure, laboratory parameters, and electrocardio-
gram (ECG) recordings at screening, baseline, regular 
intervals throughout the study day, and at the end-of-study 
visit (Day 7). Hematology, blood chemistry and urinalysis 
evaluations were also performed regularly. Adverse events 
(AEs) were recorded throughout the study, as reported by 
patients, identified by investigator questioning, or detected 
through physical examination, laboratory test or other means. 
Abnormal laboratory values were considered as AEs only 
if they produced clinical signs or symptoms, or required 
therapy. Serious AEs (SAEs) were recorded up to 4 weeks 
after the conclusion of the trial.
The secondary objectives were to assess the PK and PD 
profiles associated with a single dose of pasireotide, and to 
identify the pharmacologically active range of pasireotide 
doses. Blood samples for PK assessment were taken at 
designated time points up to 144 hours post-dose by either 
direct venipuncture or an indwelling cannula inserted 
into a forearm vein. Plasma samples were obtained after 
centrifugation of blood samples. Plasma concentrations 
of pasireotide were determined by a validated radioim-
munoassay with the lower limit of quantification (LLOQ) 
of 0.03 ng/mL (30 pg/mL). PK parameters were derived 
by non-compartmental analysis using   WinNonlin software 
(v 5.2; Pharsight Corporation, Mountain View, CA) and 
included maximum observed plasma concentration after 
drug administration (Cmax), time to reach Cmax (tmax), half-
life (t½,α, t½,β, t½,γ), area under the plasma concentration-time 
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curve calculated to the last quantifiable concentration point 
(AUClast), area under the plasma concentration-time curve 
extrapolated to infinity (AUC∞), apparent volume of distri-
bution (Vz/F), and apparent total body clearance (CL/F). All 
blood samples taken for laboratory samples were assessed 
centrally by W & T GmbH (Berlin, Germany).
A growth hormone-releasing hormone (GHRH) stimulation 
test was performed on Day −1 and 3–5 hours after pasireotide 
administration on Day 1 for PD assessment. Subjects were 
administered a GHRH bolus of 1 µg/kg at approximately 
3 hours after pasireotide administration. Plasma GH levels were 
obtained at −60 minutes and 0 minutes (just before injection of 
GHRH), and at designated time points up to 120 minutes after 
GHRH administration (ie, up to approximately 5 hours after 
pasireotide administration). Plasma GH levels were determined 
by a chemiluminescence assay with a LLOQ of 0.06 ng/mL.
Blood glucose measurement was part of the standard 
laboratory assay. Blood glucose levels were measured 
immediately before and 60 minutes after a standard lunch 
on Day −1 and Day 1, as well as 2 hours after pasireotide 
administration on Day 1, to evaluate possible drug effects 
on glycemia. Glucose levels were also measured on Day 2 
at 23 hours after pasireotide administration.
Statistical analyses
Descriptive statistics were provided for vital signs, ECG 
evaluations, standard clinical laboratory evaluations, and 
AEs. The assessment of safety/tolerability was based on the 
frequency of AEs and on the number of laboratory values 
that fell outside pre-determined ranges.
All concentrations below the LLOQ were treated as zero 
in the concentration data listings. Summary descriptive statis-
tics were provided for PK parameters. In order to determine 
the dose-proportional relationship for the PK exposures 
(Cmax, AUClast and AUC∞), linear models were fitted on the 
log-transformed PK parameters with log-transformed dose 
as the independent variable (Equation 1):
ln(PK parameter) = ln(a) + b * ln(dose) + error  (1)
The slope b and the relative 90% confidence interval (CI) 
for b were estimated. Given the dose–range ratio considered 
(highest dose/lowest dose = Rd), the critical region, within 
which the 90% CI for the slope needs to be contained in 
order to conclude dose proportionality, can be derived as 
1 + ln(0.8)/ln(Rd), 1 + ln(1.25)/ln(Rd), where (0.80, 1.25) is 
the standard acceptance interval for Rd.
Lack of fit of the model was tested for deviation from 
linearity on the log scale at the 5% significance level. This 
was done by adding a factor (dose) in the log-transformed 
linear regression model. The type I test for dose is the test 
for lack of fit. The final dose range kept in the model was 
the one for which the lack of fit test did not meet the 5% 
significance level.
The relationship between the dose of pasireotide and 
the effect on GHRH-stimulated GH secretion was investi-
gated using appropriate graphical and exploratory statistical 
  methods. Analysis of the data was performed using SAS® 
(v 8.2; SAS Institute Inc, Cary, NC). The GH ratio was calcu-
lated as the 2-hour GH AUC (AUC2h; taken between 3–5 hours 
post-dose) in each dose group divided by the 2-hour AUC on 
the control day (Day –1). A non-linear Emax sigmoid model 
(Equation 2) was used to describe the relationship between 
the pasireotide dose and the GH AUC ratio, where Emax is 
the maximum GH reduction and ED50 is the pasireotide dose 
to yield half of the maximum GH reduction:
 
GH ratio
AUC
AUC
E
ED dose
ht reat
hc ont
−= =
+
2
2
1
50
,
,
max
−   (2)
A similar analysis was performed using the equation 
above (Equation 2) with the average pasireotide plasma 
concentration over the 2-hour window during the GHRH 
challenge test (Cavg) as the independent parameter in place 
of dose, and EC50 (defined as the pasireotide concentration to 
yield half of the maximum GH reduction) in place of ED50.
Results
Subject demographics
Seventy-two healthy male subjects were enrolled. All 
subjects completed the study except for one in the lowest 
pasireotide dose cohort (1 µg) who did not return for the 
end-of-study visit. The demographic details of the volunteers 
are summarized in Table 2. All 72 subjects were included 
in all analyses.
Safety/Tolerability
Pasireotide was generally well tolerated and there were no 
reports of death, SAEs, or clinically significant changes 
in laboratory values, vital signs or ECG parameters. 
Nine subjects experienced a total of 12 AEs, eight of which 
were considered related to the study drug. Drug-related AEs 
were observed in the 1200 µg dose group only. Five AEs were 
of moderate severity and seven AEs were considered mild.
Among subjects administered pasireotide at doses lower 
than 1200 µg, two experienced an AE (one subject experi-
enced two episodes of abdominal discomfort with pasireotide 
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100 μg, both of mild intensity, and one subject experienced 
an episode of influenza of moderate intensity with pasireotide 
600 µg). These events were not considered to be related to the 
study medication. At the pasireotide 1200 µg dose, all subjects 
(n = 6) experienced at least one AE, five of whom experienced 
nausea. The AEs generally started about 1 hour after the pasir-
eotide injection and lasted for approximately 2–3 hours. None 
of these subjects received medications for treatment of an AE. 
One subject receiving placebo had an AE of oral herpes of 
moderate intensity.
AEs considered treatment related included five events of 
nausea (three mild and two moderate), and one event each of 
headache of mild intensity, dizziness of mild intensity, and 
vomiting of moderate intensity. AEs considered unrelated 
to pasireotide treatment were herpes labialis, influenza, and 
two episodes of abdominal discomfort.
Two subjects administered pasireotide 2.5 µg and 
10 µg displayed increased lipase levels of 547 U/L and 
523 U/L, respectively, 48 hours post-dose (normal range: 
23–300 U/L), which was considered possibly related to the 
study drug. Lipase levels had returned to the normal range 
when lipase levels were next measured, at the end-of-study 
visit (Day 7). One placebo recipient had lipase values four 
times greater than the ULN (1247 U/L) 24 hours after receiv-
ing placebo. In this subject, lipase levels returned to within 
the normal range at 48 hours after placebo administration. 
No clinical findings were associated with increased lipase 
levels in these subjects. Amylase levels were normal in 
these subjects.
Blood glucose levels
One hour before pasireotide administration (pre-breakfast), 
the mean glucose levels were similar between groups 
(87.7 mg/dL in the placebo group and 81.1–97.9 mg/dL with 
pasireotide 1–1200 μg). Two hours after study drug admin-
istration, the mean glucose level in the placebo group was 
82.6 mg/dL. Glucose levels in subjects administered pasir-
eotide 1–100 µg were similar to those of placebo recipients, 
whereas mean glucose levels in subjects administered pasir-
eotide $200 µg were higher than those of placebo recipients. 
In the pasireotide 200, 300, 600, and 1200 µg dose groups, 
mean glucose levels were 126.6, 116.2, 172.7, and 145.5 mg/
dL, respectively, 2 hours after pasireotide administration.
Six hours after the administration of pasireotide, only 
subjects administered the two highest doses of pasireotide 
(600 µg and 1200 µg) had glucose levels higher than those 
of placebo recipients. Twenty-three hours after the injection, 
glucose values were normal for all groups.
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Pharmacokinetics
At a dose of 1 µg, pasireotide concentrations were below the 
LLOQ (0.03 ng/mL) and this dose was therefore excluded 
from the calculation of PK parameters. As shown in Figure 2 
following a single dose of pasireotide 2.5–1200 µg, the mean 
plasma concentration versus time profiles of pasireotide 
appeared to demonstrate mono-exponential disposition for 
doses 2.5–10 µg (with an α phase), bi-exponential disposi-
tion for doses 30–300 µg (with α and β phases), and tri-
exponential disposition for doses 600–1200 µg (with α, β, 
and γ phases), which appeared to depend on the pasireotide 
plasma concentration levels in reference to the LLOQ of 
0.03 ng/mL.
As shown in Table 3, the t½ values of pasireotide in the α 
phase (t½,α: 1–2 hours) and β phase (t½,β: 7–11 hours) were 
similar across dose levels. The mean values of t½ in the   
γ phase (t½,γ) were 31.7 hours and 65.8 hours for the 600 µg 
and 1200 µg doses, respectively. Since the partial AUC in 
the γ phase at the higher dose levels (600 µg and 1200 µg) 
contributed ,15% of the total AUC∞, the t½,β could be con-
sidered as the effective elimination t½.
The peak concentration Cmax was achieved rapidly, with 
tmax occurring at approximately 0.25–0.5 hours post-dose. 
PK exposures (Cmax, AUClast, and AUC∞) were increased as 
the dose increased. The mean value of CL/F was 8–13 L/
hour across the tested doses from 100 µg to 1200 µg. 
Depending on which phase was the detectable terminal 
phase, the mean values of Vz/F varied across doses: 40 L 
for the low doses (10 µg); 100–180 L for the intermediate 
doses (30–300 µg); and 450–1200 L for the higher doses 
(600–1200 µg).
The dose proportionality assessments based on statistical 
analyses were performed for PK exposures (AUC∞, AUClast, 
and Cmax), Table 4. Across the dose range from 2.5 µg to 
1200 µg, all three PK exposure parameters exhibited good 
proportionality with the regression slope values in the 
log(exposure)-dose model being close to one, although sta-
tistically the 90% confidence limits for the slopes fell slightly 
outside the pre-defined acceptance boundary (0.964, 1.036). 
Considering the variability and small sample size per dose 
group, the slight statistical deviations from proportionality 
were not considered clinically significant. Therefore, the PK 
exposures (AUC∞, AUClast, and Cmax) of pasireotide could be 
considered to be approximately dose proportional.
Pharmacodynamics
On Day 1 in the placebo group, the mean GH AUC2h was 
22.7 ng ⋅ h/mL. No reduction in GH AUC2h was observed 
with pasireotide doses between 1 µg and 10 µg. The 
GH AUC2h decreased by approximately 45% in subjects 
administered pasireotide 30–100 µg. At pasireotide doses 
of 200 µg and higher, the GH AUC2h values decreased 
substantially to between 4.6 ng ⋅ h/mL and 1.0 ng ⋅ h/mL. 
As shown in Table 5, suppression of GH AUC2h was seen 
with pasireotide 200, 300, 600, and 1200 µg.
The dose-response (defined as GH AUC reduction) 
and exposure-response relationships of pasireotide were 
well   fitted by a direct inhibitory effect sigmoid Emax model 
(Table 6). The pasireotide dose to yield half the maximal GH 
reduction (ED50) was estimated to be 70.7 µg (approximate 
95% confidence interval [CI]: 51.4–97.3 µg). The average 
pasireotide concentration expected to yield half the maximal 
0.0
02 44 87 29 6 120 144
Pasireotide
1200 µg
600 µg
300 µg
200 µg
100 µg
30 µg
10 µg
2.5 µg
Time (h)
P
a
s
i
r
e
o
t
i
d
e
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
n
g
/
m
L
)
0.1
1.0
10.0
100.0
Figure 2 Pasireotide mean plasma concentration versus time profiles following a single subcutaneous dose of pasireotide in healthy volunteers.
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GH reduction (EC50) was 0.3 ng/mL (approximate 95% 
CI: 0.2–0.7 ng/mL).
Discussion
Following subcutaneous injection, pasireotide was well 
tolerated in healthy volunteers at doses up to 1200 µg. 
Among subjects receiving a dose of pasireotide #600 µg, 
two experienced an AE, neither of which was considered 
related to pasireotide. All six subjects who were admin-
istered pasireotide 1200 µg experienced drug-related 
AEs, with nausea being the most frequently reported. 
These events were mild to moderate in severity and did 
not require intervention. No SAEs were observed in any 
dose group.
No subjects had clinically significant changes in 
laboratory parameters, vital signs, and ECG findings 
between administration of pasireotide and the end-of-study 
  evaluation. Single doses of pasireotide 200–1200 µg were 
associated with glucose elevations in the first 2–6 hours 
post-dose compared with placebo, but this effect was 
transient and resolved within 23 hours post-dose, at 
which time glucose levels were normal for all groups. 
This profile is similar to the well-established safety 
profiles of currently available somatostatin analogs.13–17 
Similar elevations in blood glucose levels have been 
observed in clinical trials of subcutaneous pasireotide 
(200–900 µg bid) in patients with Cushing’s disease12,18 
and acromegaly.7
The PK profile of pasireotide was characterized by fast 
absorption, low clearance, long half-life, and extensive dis-
tribution in healthy volunteers. Compared with octreotide, 
which has a mean t½ of approximately 1.7 hours,19 pasireotide 
has a much longer half-life, which is not surprising consider-
ing that its chemical structure is more metabolically stable 
than that of octreotide. Pasireotide concentrations showed 
multi-exponential declines following a subcutaneous injec-
tion, and the γ phase was not always observed at low dose 
levels. Since the γ phase only contributes a small portion of 
the total AUC, it is appropriate to consider that the effec-
tive elimination   t½ is similar to the t½,β of approximately 
7–11 hours. Based on this effective elimination t½, subcuta-
neous pasireotide is suitable for a twice-daily (bid) dosing 
regimen, which is less frequent than subcutaneous octreotide 
(3–4 times/day dosing) and can thus provide greater conve-
Table 3 Summary of pharmacokinetic parameters in healthy subjects administered a single subcutaneous dose of pasireotide 2.5–1200 µg
Dose 
(μg)
n tmax 
(h)
Cmax 
(ng/mL)
AUClast 
(ng ⋅ h/mL)
AUC∞ 
(ng ⋅ h/mL)
CL/F 
(L/h)
t½,α 
(h)
t½,β 
(h)
t½,γ 
(h)
Vz/F 
(L)
2.5 6 0.25 (0.25–0.50) 0.06 ± 0.01 0.11 ± 0.09 NA* NA* 2.6 ± 1.4 NA* NA* NA*
10 6 0.25 (0.25–0.25) 0.24 ± 0.06 0.66 ± 0.25 NA* NA* 2.0 ± 0.5 NA* NA* 38.1 ± 0.0
30 6 0.25 (0.25–0.50) 0.72 ± 0.17 2.78 ± 1.02 NA* NA* 2.2 ± 0.8 7.4 ± 2.2 NA* 105.0 ± 5.7
100 8 0.50 (0.25–0.50) 2.23 ± 0.45 9.10 ± 2.37 9.59 ± 2.44 11.00 ± 2.67 1.6 ± 0.3 8.1 ± 1.4 NA* 131.0 ± 41.0
200 4 0.38 (0.25–1.00) 3.73 ± 0.90 16.8 ± 3.65 17.5 ± 3.82 11.90 ± 2.56 1.7 ± 0.6 7.8 ± 2.1 NA* 161.5 ± 33.9
300 6 0.38 (0.25–1.50) 4.71 ± 1.79 26.0 ± 6.87 27.1 ± 6.98 11.9 ± 3.88 2.4 ± 0.7 10.7 ± 1.0 NA* 180.5 ± 44.3
600 6 0.50 (0.25–1.00) 15.6 ± 3.25 75.6 ± 11.2 78.6 ± 12.3 7.82 ± 1.39 2.2 ± 0.6 9.1 ± 5.2 31.7 ± 6.5 464.0 ± 439.6
1200 6 0.50 (0.50–1.00) 22.2 ± 5.53 90.4 ± 13.2 93.6 ± 13.6 13.1 ± 2.09 1.7± 0.4 9.1 ± 2.1 65.8 ± 69.5 1190.0 ± 1572.3
Notes: *Not applicable due to limited data points in the terminal phase or the number of subjects with available parameters was less than 50% of the total enrolled subjects 
in this cohort. Data are median (range) for tmax and mean ± standard deviation for all others. At the lowest dose of 1 µg, pasireotide concentrations were below the LLOQ 
(0.03 ng/mL). For the doses between 2.5 and 30 µg, only a partial concentration versus time profile was detected (around 2–5 hours post-dose).
Abbreviations: AUC, area under the concentration–time curve; CL/F, apparent total body clearance; LLOQ, lower limit of quantification. 
Table  4  Summary  of  linear  regression  values  between  log-
parameters and log-dose (doses of pasireotide 2.5–1200 µg)
PK parameters Slope Confidence interval
Lower 90% Upper 90%
AUC∞ (ng ⋅ h/mL) 1.01 0.93 1.08
AUClast (ng ⋅ h/mL) 1.14 1.09 1.19
Cmax (ng ⋅ h/mL) 0.96 0.93 1.00
Abbreviations: AUC, area under the concentration–time curve; Cmax, maximum 
observed plasma concentration after drug administration.
Table 5 Percentage change in median GH AUC2h by dose group 
following a single subcutaneous dose of pasireotide or placebo
Dose  
(μg)
n Change in median  
GH AUC2h, %
Range of change in median 
GH AUC2h, % min, max
0 18 −11.9 −74.4, 170.0
1 6 8.1 −76.3, 33.6
2.5 6 23.8 −41.5, 125.8
10 6 1.0 −26.1, 70.4
30 6 −45.3 −66.5, 24.7
100 8 −46.2 −72.8, 575.9
200 4 −79.1 −85.3, −67.9
300 6 −86.7 −93.6, −64.9
600 6 −82.5 −96.5, −59.6
1200 6 −95.7 −97.1, −87.9
Abbreviations:  AUC,  area  under  the  concentration–time  curve;  GH,  growth 
hormone.
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nience and potentially lead to improved patient compliance 
during long-term treatment.
The exploratory GHRH stimulation test demonstrated 
that pasireotide has dose-dependent activity in suppressing 
GH secretion. The effect was not evident at the lower doses 
(1, 2.5, and 10 µg), and only a small effect was observed for 
the 30 µg and 100 µg doses. The suppression of GH secre-
tion was significant for the higher dose levels ($200 µg), 
suggesting that the exposure achieved at pasireotide doses 
$200 µg may be therapeutic for GH suppression. A Phase II 
study in patients with acromegaly has confirmed these find-
ings,7 and a large, randomized, Phase III trial using a long-
acting formulation of pasireotide   (pasireotide long-acting 
release) is ongoing.9 It is possible that the administration of 
high doses of pasireotide could induce GH suppression in 
patients with normal GH levels prior to treatment (ie, patients 
with Cushing’s disease), and further investigation in future 
studies may be of interest.
Conclusion
In summary, pasireotide demonstrated good safety, tolerability, 
and PK profiles in healthy volunteers. The enhanced binding 
profile of pasireotide, targeting sst1,2,3 and sst5, makes this agent 
a potential therapy for patients with acromegaly and NET who 
are untreated or refractory/resistant to octreotide or lanreotide, 
as well as for patients with Cushing’s disease. Ongoing Phase II 
and III studies are in progress to confirm the efficacy and safety 
of this agent in these patient populations.
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